Content about King Pharmaceuticals

February 28, 2013
Canadian provinces to cut generic payments

Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.

Canadian generic drug makers expressed dismay over a new plan to reduce reimbursements for a half-dozen generic medications in most of the country's provinces. According to published reports, a group of premiers had reached a coordinated deal to reduce the prices their governments paid for six generic drugs, hoping to save the provinces nearly $100 million.

January 25, 2013
Canadian provinces to reduce reimbursements for six generics

Canada's provincial and territorial governments have reached a deal that they said would save money on drugs, but that generic drug makers said had left them "disappointed."

NEW YORK — Canada's provincial and territorial governments have reached a deal that they said would save money on drugs, but that generic drug makers said had left them "disappointed."

October 7, 2011
Watson files for approval of generic painkiller

Watson Pharmaceuticals is looking to become the first to market a generic version of a painkiller made by Pfizer, the drug maker said Friday.

PARSIPPANY, N.J. — Watson Pharmaceuticals is looking to become the first to market a generic version of a painkiller made by Pfizer, the drug maker said Friday.

Watson said it filed a regulatory approval application with the Food and Drug Administration for morphine sulfate and naltrexone hydrochloride extended-release capsules in the 30-mg/1.2-mg, 50-mg/2-mg, 60-mg/2.4-mg, 80-mg/3.2-mg and 100-mg/4-mg strengths. The drug is a generic version of Embeda, made by Pfizer subsidiary King Pharmaceuticals.

August 24, 2011
M&A: Multitudinous and ample

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


In May, Teva beat out Valeant’s $5.7 billion offer to buy Frazier, Pa.-based Cephalon with a $6.8 billion offer of its own, acquiring Cephalon’s hefty pipeline in the process. And last month, Teva bought Taiyo Pharmaceutical Industry, Japan’s third-largest generics company, for $934 million.


August 2, 2011
Nycomed US announces executive changes

In line with its new position as a stand-alone corporation, the former U.S. subsidiary of a Swiss drug maker has appointed a new leader.

MELVILLE, N.Y. — In line with its new position as a stand-alone corporation, the former U.S. subsidiary of a Swiss drug maker has appointed a new leader.

Nycomed US announced that Brian Markison, former chairman and CEO of King Pharmaceuticals, will lead the company as president, CEO and a member of the board. The company also appointed Jeff Bailey as COO and John Golubieski as CFO. Both Bailey and Golubieski also held executive roles at King.

March 17, 2011
Report: Pfizer recalls Embeda

Pfizer is recalling a painkiller drug it acquired when it bought King Pharmaceuticals due to problems with a chemical used to deter drug abuse, according to published reports.

NEW YORK — Pfizer is recalling a painkiller drug it acquired when it bought King Pharmaceuticals due to problems with a chemical used to deter drug abuse, according to a published report.

Reuters reported that Pfizer had recalled supplies of Embeda (morphine sulfate and naltrexone hydrochloride) because the chemical that prevents the drug from being ground up or dissolved by drug abusers — naltrexone — had deteriorated in samples of the drug that Pfizer had tested.

The drug has sales of less than $70 million per year, according to Reuters.

February 14, 2011
FDA grants Acurox priority review

The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.

February 3, 2011
US WorldMeds introduces Alsuma

US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

LOUISVILLE, Ky. — US WorldMeds has announced a new treatment for migraines, the drug maker said Wednesday.

The company announced the launch of Alsuma auto-injector (sumatriptan), which injects the drug sumatriptan under the skin via a single-use, prefilled auto injector. The company is selling the drug under a licensing agreement from King Pharmaceuticals.

January 31, 2011
Pfizer: Tender offer for King completed

Pfizer has completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals, Pfizer said Monday.

NEW YORK — Pfizer has completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals, Pfizer said Monday.

Pfizer said 230.7 million shares valued at $14.25 each were tendered, representing about 92.5% of King.

Pfizer made its $3.6 billion offer for King in October 2010. The offer cleared the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on Friday.

January 28, 2011
Pfizer one step closer to completing King acquisition

Pfizer has cleared one of the main legal hurdles in its effort to purchase drug maker King Pharmaceuticals, Pfizer said Friday.

NEW YORK — Pfizer has cleared one of the main legal hurdles in its effort to purchase drug maker King Pharmaceuticals, Pfizer said Friday.

Pfizer, the world’s largest drug company, said the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had been terminated, one of the conditions necessary for the completion of Pfizer’s tender offer for King.

Pfizer announced plans in October to purchase Bristol, Tenn.-based King for $3.6 billion, or $14.25 per share.

January 27, 2011
FDA reaccepts approval application for Remoxy

The Food and Drug Administration has accepted a regulatory approval application for a pain drug that it previously had declined to approve.

CUPERTINO, Calif. — The Food and Drug Administration has accepted a regulatory approval application for a pain drug that it previously had declined to approve.

Durect announced Thursday that the FDA had accepted a resubmitted application by King Pharmaceuticals for Remoxy (oxycodone), a controlled-release painkiller designed to reduce the risks of misuse. King and Pain Therapeutics are developing the drug using Durect’s drug-delivery technology.

January 21, 2011
Pfizer extends tender offer for King

Pfizer again has extended the expiration date on its tender offer to buy Bristol, Tenn.-based King Pharmaceuticals to Jan. 28, the drug maker said Friday.

NEW YORK — Pfizer again has extended the expiration date on its tender offer to buy Bristol, Tenn.-based King Pharmaceuticals to Jan. 28, the drug maker said Friday.

Pfizer announced in October that it would buy King for $3.6 billion, or $14.25 per share. King manufactures branded prescription drugs, including several painkillers.

December 20, 2010
King, Acura seek regulatory approval for Acurox

Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

BRISTOL, Tenn. — Drug makers King Pharmaceuticals and Acura Pharmaceuticals have submitted a regulatory approval application to the Food and Drug Administration for an opioid pain reliever.

The two drug makers announced Tuesday the submission for Acurox (oxycodone hydrochloride), an immediate-release tablet for relief of moderate to severe pain.

The tablets use Acura’s aversion technology, designed to deter abuse of the drug by dissolving or crushing the pills.

December 16, 2010
Pfizer extends tender offer for King

A subsidiary of Pfizer has extended the expiration date of its tender offer to acquire all outstanding shares of common stock of King Pharmaceuticals.

NEW YORK — A subsidiary of Pfizer has extended the expiration date of its tender offer to acquire all outstanding shares of common stock of King Pharmaceuticals.

Parker Tennessee's tender offer now is scheduled to expire Jan. 21, as certain conditions to the tender offer wouldn't have been satisfied by the previously scheduled expiration date — which was Dec. 17 — including the expiration or earlier termination of any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

November 21, 2010
Deadline for Pfizer's tender offer for King extended

Pfizer has extended the deadline of its $3.6 billion offer to buy King Pharmaceuticals, Pfizer...

NEW YORK Pfizer has extended the deadline of its $3.6 billion offer to buy King Pharmaceuticals, Pfizer said Monday.

 

Pfizer said it had extended its tender offer to Dec. 17 because certain conditions had not been met, but the two companies plan to have it finished by the end of this year or the beginning of next year.

 

 

King, based in Bristol, Tenn., specializes in branded opioid prescription painkillers.

 

October 21, 2010
Pfizer makes official tender offer for King

Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or...

NEW YORK Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or $14.25 per share, Pfizer said Friday.

 

The offer constitutes a 40% premium over the closing price of King’s stock on Oct. 11, when Pfizer originally made the offer. King, based in Bristol, Tenn., specializes in pain medications designed to deter misuse and abuse, and Pfizer said the acquisition would enhance its position in the pain-relief market.

 

 

The offer expires at midnight on Nov. 19.

 

October 11, 2010
Pfizer to acquire King Pharmaceuticals

Pfizer will buy King Pharmaceuticals for $3.6 billion, Pfizer said Tuesday....

NEW YORK Pfizer will buy King Pharmaceuticals for $3.6 billion, Pfizer said Tuesday.

 

The world’s largest drug maker announced that it had agreed to acquire Bristol, Tenn.-based King for $14.25 per share, which it said was a 40% premium over the Monday closing price of King’s stock.

 

 

August 29, 2010
King names new chief commercial officer

Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing,...

BRISTOL, Tenn. Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing, managed care, sales operations and business analytics for the drug maker.

BRISTOL, Tenn. Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing, managed care, sales operations and business analytics for the drug maker.

April 12, 2010
FDA to begin removing inhalers containing CFC propellants from market

The Food and Drug Administration will start phasing out asthma and chronic obstructive pulmonary disease...

SILVER SPRING, Md. The Food and Drug Administration will start phasing out asthma and chronic obstructive pulmonary disease inhalers that contain ozone-depleting chlorofluorocarbons in less than two months, the agency announced Tuesday.